---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-277530"
form_type: "8-K"
ticker: null
cik: "0001971543"
company_name: "Mural Oncology plc"
filed_at: "2023-11-15T23:59:59+00:00"
generated_at: "2026-06-08T02:50:07.715587+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Mural Oncology spins off from Alkermes with $275M funding; nemvaleukin trials readout in 1Q2025

## Summary
- Spin-off completed Nov 15, 2023; Mural shares trade on Nasdaq under 'MURA' starting Nov 16.
- $275M committed funding provides cash runway projected into 4Q 2025.
- Lead candidate nemvaleukin in two potentially registrational trials; top-line data expected 1Q 2025.
- Preclinical IL-18 and IL-12 programs; development candidate nominations planned in 2024.
- Executive team includes CEO Caroline Loew, CFO Adam Cutler, CMO Vicki Goodman; board chaired by Scott Jackson.

## SEC filing metadata
- accession: 0001193125-23-277530
- form_type: 8-K
- cik: 0001971543
- company_name: Mural Oncology plc
- filed_at: 2023-11-15T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.01, 3.03, 5.03, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1971543/000119312523277530/0001193125-23-277530-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1971543/000119312523277530/d319165d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-277530
- JSON: https://secwatch.observer/filing/0001193125-23-277530.json
- Plain text: https://secwatch.observer/filing/0001193125-23-277530.txt

## Key facts
- Executive change
  Caroline Loew, Ph.D. was elected as Chief Executive Officer at Mural Oncology plc.
  - Action: elected
  - Role: Chief Executive Officer
  source text: In connection with the Separation, the following individuals were elected to the positions set forth in the table below: Name Position Caroline Loew, Ph.D. Chief Executive Officer
  evidence_url: https://www.sec.gov/Archives/edgar/data/1971543/000119312523277530/0001193125-23-277530-index.htm
- Executive change
  Caroline Loew, Ph.D. resigned as Principal Financial Officer and Principal Accounting Officer at Mural Oncology plc.
  - Action: resigned
  - Role: Principal Financial Officer and Principal Accounting Officer
  source text: In connection with the Separation, Dr. Caroline Loew resigned as Principal Financial Officer and Principal Accounting Officer, effective as of November 15, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1971543/000119312523277530/0001193125-23-277530-index.htm
- Executive change
  Adam Cutler was appointed as Principal Financial Officer and Principal Accounting Officer at Mural Oncology plc.
  - Action: appointed
  - Role: Principal Financial Officer and Principal Accounting Officer
  source text: In connection with the Separation, Adam Cutler was appointed as Principal Financial Officer and Principal Accounting Officer, effective as of November 15, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1971543/000119312523277530/0001193125-23-277530-index.htm
- Governance Changes
  Mural Oncology plc: Amended and restated Memorandum and Articles of Association (Constitution) (effective 2023-11-15).
  - Change: charter amendment
  - Effective: 2023-11-15
  source text: The Memorandum and Articles of Association of Mural (the “Constitution”) was amended and restated, effective November 15, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1971543/000119312523277530/0001193125-23-277530-index.htm
- M&A Transactions
  Mural Oncology plc completed a disposition involving Alkermes plc (closed 2023-11-15).
  - Action: disposition
  - Counterparty: Alkermes plc
  - Closing: 2023-11-15
  source text: On November 15, 2023, Alkermes plc (“Alkermes”) completed the previously announced separation (the “Separation”) of its oncology business into Mural Oncology plc (“Mural”), a new, independent, publicly-traded company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1971543/000119312523277530/0001193125-23-277530-index.htm
- Material Agreements
  Mural Oncology plc entered into Lease Assumption Agreement with Alkermes Subsidiary (effective 2023-11-13).
  - Action: entry
  - Agreement: lease
  - Counterparty: Alkermes Subsidiary
  - Effective: 2023-11-13
  source text: Alkermes Subsidiary entered into an assignment and assumption of lease agreement (the "Lease Assumption Agreement") with Mural Subsidiary, dated as of November 13, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1971543/000119312523277530/0001193125-23-277530-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.